Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — H1 2026 Earnings Presentation
27 slides from Emvision Medical Devices's earnings presentation, Feb 23, 2026
Slide 1: EMVision Medical Devices 1H26 Presentation
emvision.com.au For personal use only EMVision Medical Devices (ASX:EMV) 1H26 Presentation First Responder February 2026 Bedside Scanner Pre-hospital scanner
Slide 2: Disclaimer
DISCLAIMER This Presentation has been prepared by EMVision Medical Devices Ltd (ACN 620 388 230) (the “Company”). This Presentation is for information purposes only and should be read in conjunction with the most recent financial reports and other documents lodged by the Company with the Australian
Slide 3: Agenda
AGENDA For personal use only Introduction to EMVision 1H26 Highlights & Financial Performance Outlook Appendix 3
Slide 4: Introduction to EMVision
For personal use only INTRODUCTION TO EMVISION
Slide 5: Introduction to EMVision
INTRODUCTION TO EMVISION Building a new category of point-of-care neurodiagnostic devices for acute neurological emergencies For personal use only emu (in-hospital) Over 15 years and > $60m invested in innovative research and development in radio Novel technology frequency sensing and imaging techno
Slide 6: Why we are starting in stroke
WHY WE ARE STARTING IN STROKE Stroke is a leading cause of mortality and disability globally For personal use only Modern stroke treatments are highly 1 in 4 people will have a stroke in their lifetime effective, but they are time-sensitive and require determination of stroke type Around two-thirds
Slide 7: Stroke requires urgent diagnosis
STROKE REQUIRES URGENT DIAGNOSIS Conventional CT imaging is critical in stroke diagnosis but not widely accessible at the point of care Mobile Stroke Units (MSUs) are For personal use only custom-built ambulances fitted with a mobile CT Portable Lightweight Cost Non- Conventional CT Mobile CT Scanne
Slide 8: EMVision in the stroke care pathway
EMVISION IN THE STROKE CARE PATHWAY Saving time and reducing uncertainty at the point of care For personal use only The emu provides early stroke detection and The First Responder equips paramedics with classification at the point-of-care to enable a tool to identify and classify stroke in the pre-
Slide 9: Market opportunity
MARKET OPPORTUNITY Multi-billion-dollar addressable market for emu and First Responder emu Addressable Market First Responder Addressable Market For personal use only HOSPITALS ROAD & AEROMEDICAL AMBULANCES US GER, FR, UK AUS Dev. ASIA US GER, FR, UK AUS Dev. ASIA 10,200 5,960 545 12,850 60,000 58,0
Slide 10: 1H26 Highlights & Financials
For personal use only 1H26 HIGHLIGHTS & FINANCIALS
Slide 11: Key highlights
KEY HIGHLIGHTS For personal use only emu (in-hospital) First Responder (pre-hospital) Commercial • All six Pivotal (Validation) Trial locations • Aeromedical Retrieval Study recruiting • Strong balance sheet with $17.5m cash, activated, recruiting and accelerating. and encouraging preliminary resear
Slide 12: Profit and loss
PROFIT AND LOSS For the half ended 31 December 2025 AUD 1H26 1H25 For personal use only Income Commentary Grant income 1,205,008 1,645,576 Other income 50,886 148,861 • Total non-dilutive grant income and R&D tax R&D rebate 2,608,173 1,694,120 incentive income of $3.8 million in the half year. Inter
Slide 13: Balance sheet
BALANCE SHEET As at 31 December 2025 Commentary AUD 31 December 2025 30 June 2025 • Cash balance increased following completion of A$14.0 million capital raising (pre-costs) in September For personal use only Cash 17,545,236 10,456,814 2025. Other financial assets 14,588 73,651 Other current assets
Slide 14: Cashflow
CASHFLOW For the half ended 31 December 2025 For personal use only AUD 1H26 1H25 Commentary Receipts from customers (inc. GST) 900,864 656,797 Payments to suppliers & employees (inc. GST) (6,967,813) (5,802,260) • Proceeds from issuance of shares reflect Interest received 133,924 318,952 the Company
Slide 15: Outlook
For personal use only OUTLOOK
Slide 16: 2026 clinical & product milestones
2026 CLINICAL & PRODUCT MILESTONES Six clinical studies driving technology development, evidence generation and commercialisation momentum emu First Responder For personal use only 1. Pivotal (Validation) Trial 4. Aeromedical Study 2. Continuous Innovation Study 5. Mobile Stroke Unit Study 3. Region
Slide 17: emu Pivotal (Validation) Trial
EMU PIVOTAL (VALIDATION) TRIAL Current Status 2025 Q3 • All six primary investigational sites live and enrolling Data Safety Monitoring For personal use only • Data quality verified 2025 Q3 Board • Study conduct expanded to network sites (2nd Mount Sinai & Steering Meeting #1 Memorial Hermann sites)
Slide 18: First Responder clinical and market access roadmap
FIRST RESPONDER CLINICAL AND MARKET ACCESS ROADMAP Aeromedical Study For personal use only Healthy Volunteer Study Complete RFDS Feasibility Study In progress Mobile Stroke Unit Study Workflow & Data 510(k) Submission Collection Study In progress Substantial equivalence testing (i.e. First Responder
Slide 19: Commercialisation roadmap
COMMERCIALISATION ROADMAP • emu → De Novo For personal use only Regulatory Clearance • First Responder → 510(k) • EU and Australia approval post FDA Revenue Model Capital Consumables Servicing • Clinical & economic benefit evidence Reimbursement • emu → NTAP & DRG incorporation Pathway Coupling medi
Slide 20: Initial commercialisation strategy
INITIAL COMMERCIALISATION STRATEGY Targeted launch into the US expanded ‘Stroke Belt’ Market Launch High Priority Stroke Belt Targets For personal use only Comprehensive Primary Stroke Critical Access Stroke Centers Centers Hospitals 70 400 330 emu 22% higher death rate from stroke Academic- Advance
Slide 21: Longer term growth strategy
LONGER TERM GROWTH STRATEGY Initial US launch used as playbook for national scaling, geographic expansion and indication extension For personal use only US National Penetration International Expansion New Indications • Controlled national rollout, • Initially target European countries • Traumatic Br
Slide 22: Capital structure
CAPITAL STRUCTURE ASX Ticker: EMV Strong Capital Management Track Record For personal use only Share Price (20 Feb 2026) $1.75 Historic Funding Sources Shares on issue 92.9m 40 Total Options on issue 7.4m 35 30 Total Performance Rights on issue 0.34m 25 A$ MILLION Market Capitalisation $162.6m 20 15
Slide 23: Appendix
For personal use only APPENDIX
Slide 24: Clinical feedback
CLINICAL FEEDBACK Professor Geoffrey Donnan AO For personal use only Stroke Neurologist “It cannot be underestimated how important this cutting-edge technology could become for future stroke Co-chair ASA, Past-President of World Stroke management.” Organization Professor Stephen Davis AO Stroke Neur
Slide 25: Growing international engagement and recognition
GROWING INTERNATIONAL ENGAGEMENT AND RECOGNITION CONFERENCES AWARDS OTHER UPCOMING Conferences Presentations • Mayo Clinic 17th Annual Stroke and For personal use only Cerebrovascular Disease Review • US Military Health System Research Symposium • Novel Treatments of Acute Brain Injury emu Pivotal T
Slide 26: Technology overview
TECHNOLOGY OVERVIEW Mobile and rapid neurodiagnostic modality for pre-hospital and bedside evaluation For personal use only Antennas Dielectric contrast Array of antennas send Signals influenced by Algorithm Portfolio non-ionizing ultra-high dielectric properties of Signals obtained in minutes frequ
Slide 27: 'EMView' emu study
‘EMVIEW’ EMU STUDY High diagnostic accuracy rates for identifying and classifying stroke For personal use only Highlights • 300-patient study at 3 Australian Comprehensive Stroke Centers. "The results are very encouraging, particularly as related to • Hardware verification, safety, and AI algorithm
EMVision Medical Devices — H1 2026 Earnings Presentation on 6ix